Opioid-induced Constipation Clinical Trial
Official title:
Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol. A One-year Follow-up Study
Opioid-induced constipation (OIC) is a common feature in patients treated with strong opioids. Such medication is often prescribed together with a laxative (osmotic, emollient), with effectiveness depending on the individual patient. Peripherally-acting, mu-opioid receptor antagonists (PAMORAs), such as Naloxegol, have proven to be effective against OIC in patients with inadequate response to laxatives without reducing opioid analgesic effect. However, evidence regarding efficacy and safety on patients with cancer is still scarce. The objective of this study was to analyze the efficacy of naloxegol in a real-world setting by assessing Quality of Life outcomes, and to obtain data on its safety in the long term in patients with cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01965652 -
Long Term Safety of Naldemedine
|
Phase 3 | |
| Recruiting |
NCT05149833 -
European Study of Opioid Induced Constipation
|
||
| Completed |
NCT01186770 -
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
|
Phase 3 | |
| Completed |
NCT02270983 -
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
|
Phase 2 | |
| Completed |
NCT00640146 -
Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures
|
Phase 2 | |
| Terminated |
NCT01696643 -
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
|
Phase 3 | |
| Completed |
NCT01993940 -
Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation
|
Phase 3 | |
| Terminated |
NCT00399659 -
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
|
Phase 3 | |
| Terminated |
NCT01901302 -
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
|
Phase 3 | |
| Withdrawn |
NCT00858754 -
Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
|
Phase 4 | |
| Completed |
NCT05770960 -
Colonic Motor Patterns in Healthy Volunteers
|
Phase 4 | |
| Terminated |
NCT01384292 -
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
|
Phase 3 | |
| Completed |
NCT00672477 -
Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
|
Phase 4 | |
| Recruiting |
NCT03687268 -
Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation
|
Phase 3 | |
| Completed |
NCT00672139 -
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
|
Phase 4 | |
| Terminated |
NCT01901341 -
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
|
Phase 3 | |
| Recruiting |
NCT03720613 -
Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain
|
||
| Completed |
NCT01368562 -
Compassionate Use Study of Methylnaltrexone
|
N/A | |
| Completed |
NCT01040637 -
A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05133076 -
Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications
|
Phase 2 |